Our Mission

At Alector, we are on a mission to slow the progression of neurodegenerative diseases and to one day prevent their occurrence.

Currently, 55 million people are living with dementia, with more than 10 million new cases diagnosed each year. These cases of dementia include conditions such as Alzheimer’s disease, which affects approximately 24 million people worldwide, and frontotemporal dementia, which affects an estimated 50,000 to 60,000 in the United States and about 110,000 in the European Union. Neurodegeneration also leads to disorders beyond dementia, for instance, over 10 million people are living with Parkinson’s disease globally. As we age, the likelihood of being diagnosed with a neurodegenerative disease increases, and these conditions – marked by the progressive damage and loss of nerve cells – remain without a cure.

We envision a world where individuals retain their full brain function and cognitive faculties throughout life – a world where neurodegeneration and dementia are history.

Our mission is grounded in scientific innovation. With a deep commitment to understanding the underlying mechanisms that contribute to neurodegenerative diseases, we are focused on developing therapies that remove toxic proteins, replace missing proteins, and restore the function of immune and nerve cells.

Driven by insights in human genetics, neuroscience, and immunology, and by applying novel technologies, we are advancing the development of new treatments that have the potential to transform the landscape of neurodegenerative disease treatment and improve patient outcomes.